AUS
NZ
UK
CA
USA
IND
Highlights
- Trump moves to level playing field between pills and biologics
- Industry sees drop in funding for small molecule drug development
- Bipartisan momentum builds for policy adjustment
In a bold policy initiative, U.S. President Donald Trump has directed his administration to revisit a controversial aspect of the Inflation Reduction Act (IRA) that has been drawing fire from pharmaceutical companies. The focus is on what the industry calls the “pill penalty”—a rule that accelerates Medicare price negotiations for small molecule drugs like pills and tablets, while giving biologic drugs a longer exemption period.
Under the current IRA structure, small molecule drugs become eligible for Medicare negotiations just nine years after FDA approval, while biologics—larger, more complex medicines like injectables—are exempt for 13 years. This four-year gap has been a sticking point for drugmakers, who argue that it discourages innovation and pushes investment toward more costly and specialized biologics.
President Trump’s executive order instructs Health and Human Services Secretary Robert F. Kennedy Jr. to work with Congress on amending this policy. The goal is to bring parity between the treatment of small molecule drugs and biologics in Medicare negotiations. While the directive doesn’t change the law directly, it signals a clear shift in tone and opens the door for legislative reform.
This comes as data shows a nearly 70% decline in early-stage funding for small molecule drug development since the IRA was enacted. The pharmaceutical industry warns that such a trend could significantly reduce the number of widely accessible, lower-cost treatments for common conditions.
Companies like Pfizer (NYSE:PFE), Merck & Co. (NYSE:MRK), and Bristol Myers Squibb (NYSE:BMY)—all heavily involved in small molecule drug development—could benefit from a potential policy realignment. A study by the University of Chicago has also projected that the current structure could result in 188 fewer small molecule drugs reaching the market.
Lawmakers in North Carolina have already introduced bipartisan legislation that mirrors Trump’s proposal, signaling growing support on Capitol Hill.
The executive order also outlines broader reforms including potential updates to Medicare pricing models, steps to curb anti-competitive behavior, and expanded drug importation measures to reduce healthcare costs.
While the future of drug pricing reform remains fluid, this development has been seen as a potential tailwind for major pharmaceutical players, especially those with deep pipelines of small molecule treatments. Investors and industry watchers alike will be monitoring legislative progress closely as these proposals unfold.
